Assignee
ALDEYRA THERAPEUTICS INC
US·37 granted patents·27 pending applications·462 citations·filing 2014–2024
Top patents by PatentIndex Score
64 records- 0198US11724987B2Compositions and methods of treating retinal diseaseALDEYRA THERAPEUTICS INC·Filed 2021·Granted Aug 15, 2023·7 cites·9 claims
- 0298US11007157B2Toxic aldehyde related diseases and treatmentALDEYRA THERAPEUTICS INC·Filed 2020·Granted May 18, 2021·15 cites·41 claims
- 0398US10913722B2Compositions and methods of treating retinal diseaseALDEYRA THERAPEUTICS INC·Filed 2019·Granted Feb 9, 2021·15 cites·8 claims
- 0498US10202348B2Compositions and methods of treating retinal diseaseALDEYRA THERAPEUTICS INC·Filed 2018·Granted Feb 12, 2019·25 cites·9 claims
- 0598US9896419B2Compositions and methods of treating retinal diseaseALDEYRA THERAPEUTICS INC·Filed 2017·Granted Feb 20, 2018·28 cites·6 claims
- 0698US9650342B2Compositions and methods of treating retinal diseaseALDEYRA THERAPEUTICS INC·Filed 2016·Granted May 16, 2017·28 cites·11 claims
- 0797US11771664B2Toxic aldehyde related diseases and treatmentALDEYRA THERAPEUTICS INC·Filed 2022·Granted Oct 3, 2023·4 cites·16 claims
- 0897US11701331B2Toxic aldehyde related diseases and treatmentALDEYRA THERAPEUTICS INC·Filed 2021·Granted Jul 18, 2023·7 cites·41 claims
- 0997US11459300B2Deuterated compounds and uses thereofALDEYRA THERAPEUTICS INC·Filed 2021·Granted Oct 4, 2022·10 cites·20 claims
- 1097US11046650B2Deuterated compounds and uses thereofALDEYRA THERAPEUTICS INC·Filed 2019·Granted Jun 29, 2021·16 cites·19 claims
- 1197US10550085B2Deuterated compounds and uses thereofALDEYRA THERAPEUTICS INC·Filed 2016·Granted Feb 4, 2020·20 cites·20 claims
- 1296US11845722B2Deuterated compounds and uses thereofALDEYRA THERAPEUTICS INC·Filed 2022·Granted Dec 19, 2023·7 cites·22 claims
- 1396US11197821B2Formulations for treatment of dry eye diseaseALDEYRA THERAPEUTICS INC·Filed 2019·Granted Dec 14, 2021·12 cites·24 claims
- 1496US10588874B2Toxic aldehyde related diseases and treatmentALDEYRA THERAPEUTICS INC·Filed 2019·Granted Mar 17, 2020·20 cites·41 claims
- 1596US10543181B2Toxic aldehyde related diseases and treatmentALDEYRA THERAPEUTICS INC·Filed 2019·Granted Jan 28, 2020·17 cites·30 claims
- 1696US10213395B2Toxic aldehyde related diseases and treatmentALDEYRA THERAPEUTICS INC·Filed 2017·Granted Feb 26, 2019·24 cites·40 claims
- 1796US9364471B2Compositions and methods of treating retinal diseaseALDEYRA THERAPEUTICS INC·Filed 2014·Granted Jun 14, 2016·26 cites·13 claims
- 1896US9265759B2Compositions and methods of treating retinal diseaseALDEYRA THERAPEUTICS INC·Filed 2014·Granted Feb 23, 2016·28 cites·5 claims
- 1995US12097188B2Compositions and methods for the treatment of macular degenerationALDEYRA THERAPEUTICS INC·Filed 2023·Granted Sep 24, 2024·1 cites·19 claims
- 2095US11129823B2Combination treatment of ocular inflammatory disorders and diseasesALDEYRA THERAPEUTICS INC·Filed 2017·Granted Sep 28, 2021·12 cites·4 claims
- 2195US9687481B2Toxic aldehyde related diseases and treatmentALDEYRA THERAPEUTICS INC·Filed 2014·Granted Jun 27, 2017·28 cites·35 claims
- 2295US2025127733A1Toxic aldehyde related diseases and treatmentALDEYRA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2394US11312692B1Polymorphic compounds and uses thereofALDEYRA THERAPEUTICS INC·Filed 2021·Granted Apr 26, 2022·11 cites·19 claims
- 2494US10426790B2Treatment of allergic eye conditions with cyclodextrinsALDEYRA THERAPEUTICS INC·Filed 2017·Granted Oct 1, 2019·20 cites·30 claims
- 2594US10111862B2Traps in the treatment of macular degenerationALDEYRA THERAPEUTICS INC·Filed 2014·Granted Oct 30, 2018·26 cites·24 claims
- 2693US11786518B2Ophthalmic formulations and uses thereofALDEYRA THERAPEUTICS INC·Filed 2020·Granted Oct 17, 2023·7 cites·23 claims
- 2793US11583529B2Treatment of inflammatory disordersALDEYRA THERAPEUTICS INC·Filed 2021·Granted Feb 21, 2023·7 cites·6 claims
- 2893US11040039B2Treatment of inflammatory disordersALDEYRA THERAPEUTICS INC·Filed 2018·Granted Jun 22, 2021·16 cites·7 claims
- 2993US10414732B2Polymorphic compounds and uses thereofALDEYRA THERAPEUTICS INC·Filed 2018·Granted Sep 17, 2019·20 cites·15 claims
- 3092US12128013B2Toxic aldehyde related diseases and treatmentALDEYRA THERAPEUTICS INC·Filed 2023·Granted Oct 29, 2024·0 cites·20 claims
- 3192US11911385B1Methotrexate treatment methodsALDEYRA THERAPEUTICS INC·Filed 2022·Granted Feb 27, 2024·1 cites·20 claims
- 3288US2024174614A1Compositions and methods of treating retinal diseaseALDEYRA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3386US12064516B2Pharmaceutical formulations and uses thereofALDEYRA THERAPEUTICS INC·Filed 2021·Granted Aug 20, 2024·1 cites·10 claims
- 3485US2025144080A1Compositions and methods for the treatment of macular degenerationALDEYRA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3584US12240816B2Deuterated compounds and uses thereofALDEYRA THERAPEUTICS INC·Filed 2023·Granted Mar 4, 2025·0 cites·20 claims
- 3684US2023041335A1Compositions and methods of treating retinal diseaseALDEYRA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3781US12029735B2Polymorphic compounds and uses thereofALDEYRA THERAPEUTICS INC·Filed 2021·Granted Jul 9, 2024·1 cites·21 claims
- 3880US12005061B2Ophthalmic formulations of methotrexateALDEYRA THERAPEUTICS INC·Filed 2022·Granted Jun 11, 2024·0 cites·27 claims
- 3979US12098132B2Process for preparation of aldehyde scavenger and intermediatesALDEYRA THERAPEUTICS INC·Filed 2020·Granted Sep 24, 2024·1 cites·9 claims
- 4079US12006298B2Polymorphic compounds and uses thereofALDEYRA THERAPEUTICS INC·Filed 2019·Granted Jun 11, 2024·1 cites·20 claims
- 4178US12005060B2Ophthalmic formulations of methotrexateALDEYRA THERAPEUTICS INC·Filed 2022·Granted Jun 11, 2024·0 cites·16 claims
- 4277US2023293527A1Treatment of inflammatory disordersALDEYRA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4375US2023248727A1Treatment of inflammatory disordersALDEYRA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4474US2024197740A1Methotrexate treatment methodsALDEYRA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4570US2024139173A1Ophthalmic formulations and uses thereofALDEYRA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4668US2022354857A1Aldehyde conjugates and uses thereofALDEYRA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4766US2022133629A1Formulations for treatment of dry eye diseaseALDEYRA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4866US2020246345A1Aldehyde conjugates and uses thereofALDEYRA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4965US2022370460A1Ophthalmic formulations of methotrexateALDEYRA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 5064US2022184057A1Combination treatment of ocular inflammatory disorders and diseasesALDEYRA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
Showing the top 50 of 64 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →